Public-registry site landscape for NCT07730515, a Non-hodgkin Lymphoma study sponsored by Evopoint Biosciences Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07730515 (registry record) |
| Sponsor | Evopoint Biosciences Inc. |
| Condition(s) | Non-hodgkin Lymphoma; Peripheral T-cell Lymphoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 1 |
| Site countries | China |
At Shanghai Cancer Center — one of the facilities listed on this trial — 40 other studies are actively recruiting Non-hodgkin Lymphoma patients at the same facility (public registry, as of July 2026). Facility-level recruiting density is one of the strongest public correlates of enrollment pace in an indication.
Eichor generates a preliminary site-risk snapshot for NCT07730515 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →